SRR2932844
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- PANCREAS_BETA_CELLS+0.440
- G2M_CHECKPOINT+0.390
- MYC_TARGETS_V1+0.380
- CHOLESTEROL_HOMEOSTASIS+0.360
- MTORC1_SIGNALING+0.320
- TNFA_SIGNALING_VIA_NFKB+0.320
- OXIDATIVE_PHOSPHORYLATION+0.230
- P53_PATHWAY+0.210
- SPERMATOGENESIS+0.210
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- MYOGENESIS-0.340
- ANGIOGENESIS-0.330
- INTERFERON_GAMMA_RESPONSE-0.280
- INTERFERON_ALPHA_RESPONSE-0.260
- HEDGEHOG_SIGNALING-0.250
- UV_RESPONSE_DN-0.250
- NOTCH_SIGNALING-0.230
- APICAL_JUNCTION-0.220
- COAGULATION-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8027196b-a80b-4759-872d-b72c98905451 | — | — | 0.847 |
| 2 | c6c161fd-9f0a-4ad5-96ba-b9ce811348fc | — | — | 0.814 |
| 3 | TCGA-IQ-A61G-01A-11R-A30B-07 | — | — | 0.804 |
| 4 | SRR26320071 | — | — | 0.781 |
| 5 | 6bc5d616-670c-4778-a769-d5b64fc51d8e | — | — | 0.781 |
| 6 | TCGA-YF-AA3M-01A-11R-A42T-07 | — | — | 0.765 |
| 7 | TCGA-77-7463-01A-11R-2045-07 | — | cohortSQ1 | 0.763 |
| 8 | SRR2932846 | — | — | 0.761 |
| 9 | SRR35579804 | — | C | 0.757 |
| 10 | SRR2932839 | — | — | 0.755 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.440 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.360 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.180 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.110 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |